Latest Chronic Kidney Disease (CKD) News
A post-hoc analysis was conducted on the effect of saxagliptin 2.5 mg and 5 mg vs. placebo on glycemic measures.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
Notably, gliclazide did not appear superior to other sulfonylureas.
Study implicates higher consumption of advanced glycation end products through dietary fat.
Nearly 28% of study participants demonstrated difficulty with 1 or more activities of daily living, a history of falls, and cognitive impairment.
Patients with depression were younger, had higher eGFR, and more comorbidities.
Highest vs lowest quartile of intake is associated with a 40% increased risk.
Patients with non-dialysis chronic kidney disease (CKD) may be at elevated risk for hip fracture, according the Journal of Bone and Mineral Research.
Odds of cardiovascular mortality 14.8% higher in black Americans with both conditions.
High potassium levels associated with the use of renin-angiotensin-aldosterone system inhibitors limit their use in CKD patients.
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
CKD associated with dysmotility and reduces fasting and post-prandial small bowel water.
High vs. low fitness levels in midlife lowered CKD risk in later life by 34%.
Researchers find an increased risk for elevated serum creatinine, but not chronic kidney disease or all-cause mortality.
The researchers found no relationship between poor quality of life and CKD progression.
Chronic Kidney Disease (CKD) Videos
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)